リスジプラム
“Risdiplam in Type 1 Spinal Muscular Atrophy”. The New England Journal of Medicine (Boston, Massachusetts, United States of America: NEJM Group (Massachusetts Medical Society)) 384 (10): 915-923. doi:10.1056/NEJMoa2009965. ISSN 00284793. LCCN 20-20456. OCLC 231027780. PMID 33626251.
↑ Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, Jablonski P, Jacobsen B, Khwaja O, Kletzl H, Ko CP, Kustermann S, Marquet A, Metzger F, Mueller B, Naryshkin NA, Paushkin SV, Pinard E, Poirier A, Reutlinger M, Weetall M, Zeller A, Zhao X, Mueller L (August 2018). “Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)”.